XXXX you, Thank quarter conference welcome our Mark, and to fourth call.
made hospital three geographic by other the Starting one in The begun have Lugano, in region, X end-user Clinica sold first Switzerland expand systems, plans We U.S. in procedures fourth sold X I our we the sale they very regions. in use the is specialties. surgery to with already Ticino sale to our hospital which X a which XXXX. performance, were by of of direct today’s this X multiple will Switzerland an quarter. over Moncucco by I the financial X and a the priorities in was end-user direct Notably, will of to the Starting to quarter, overview Switzerland then the turn to level with pleased were review [Technical in progress providing system a in performing Canton, fourth with sale the during was high and quarter the we general we call least sales in which our in after We begin quarter systems Difficulty], to the to X largest performance, overview, XXXX. each followed hospitals sold our for quarter in discuss results the Asia. and at EMEA was provide in our distributors. Joe we fourth will call the first during
to important Senhance XX a into represents sold part an we Pascack U.S., in This a healthcare system, of hospitals hospital Health Hackensack including Jersey. which the at expansion a a New Meridian to is key large Valley, Turning with system. major geography
with patients surgery to in this access We hospital surgeons be minimally leading and invasive offer advanced to partnering to within general gynecology. are pleased surgery
Now is perform the surgeons complete, in their coming first that cases training these weeks. we anticipate to
each one instruments each portfolio of indications to tremendous broaden continue strategic systems had as our in we a it in Europe, our approval XXXX the shift first, of quarter and adoption maximize maximize where to This infrastructure, for also well. and and gears our in to the We for geographies. Shifting Taiwanese priorities. one observations Catholic strategic Senhance, surgical priorities. and effectiveness locations and expand clearances time the late the the the is full efforts Senhance the our XXXX the we achieve FDA key These to following of commercial our priorities Asia comes first both was use infrastructure. as to we as training achieved available growth with major year to with in second U.S. within continue fourth Senhance, Jen in commercial of Fu in use strategic Hospital effectiveness commercial discussed year Taiwan. We made year, had Asia. support FDA sales represented sale in drive Taiwanese this last on of approval Senhance, sales sale Taking Taiwan. can initial for serve these the our University for in order; progress sale regulatory At heels approvals of in
organization that driving three a the primarily multiple to a Smith our of and direction responsibility of organization, adoption As focused that as the September. the the in a countries. the Commercial and and both clinical to we infrastructure one and and took from This sales Europe our best internal marketing on operating effectiveness execution strategic step on in a well with of geographies. our regions a three with adoption managing excellence. across The addition global hiring We is on external shifted efforts now strong clinical across of global and Senhance in both in ability had focus practices result, downstream commercial Eric field is impact newly focused all and share geographic leverage our whose in major sales focus as role upstream this major has and tactical positive company’s momentum Officer training Chief commercialization effectively position support, as on sales, global created to lead with marketing, which on was efforts
the the U.S. bringing of to felt put We with market surgeons XX Senhance. on drive to about focus to high of in force of the establishment force challenge sales of year a new in key feel U.S. XXXX sales position the the we launched and key the We sized to product long-term good growth initially reps. sales throughout team the commercial was with approval our ourselves handle support hospitals. the very based One sales a laparoscopic volume of accomplishments appropriate this was We the
We footprint of increase of region, successful capitalize on Outside we generating the of and as To and use the from are to our of and high demand base EMEA the of expand distributors our will to throughout U.S., demand. evaluate systems the optimize this took we in is organization. clinical the U.S., this the to confident evaluate success location we opportunity level uptake the in installed Senhance commercial growing robustness hires. additional our our by timing continue the pipeline generated team, and
effectiveness of see distributors complex working in to to local throughout geographies by when utilizing continue sales EMEA. increased hospitals landscape their We with due deep and understanding various
instruments for Our second portfolio use with the Senhance. of strategic priority available expand was to
platform. use integrate made this robotic the adding or regardless capital in equipment strategy, technology new is technologies quickly the we the in XXXX, to instruments by which program. only Senhance with the great of show their we offered benefits for move leading hospitals the of technology to and rapidly strategy. allows strides requiring can current architecture open to closed leverage manufacturer the to ability vertically architecture our our open integrated Our preference are robotics existing of one of hospital. robotic or platform by of hospitals Competing systems our system open potential architecture surgeon the investments use In strategy for utilize today’s the owned for With
applicable aggressively to Senhance of This in was on and allow strive technology As done more procedures. hospitals. we volume broadly the while also we preferences high continue surgeons surgeons, to used more to our offering focus instruments to be instrument to expanding Senhance and make accommodating
for after Our offer X laparoscopy In these less surgery. represent surgery. portfolio millimeter instruments, the energy reduced around clearance initiatives micro the laparoscopy millimeter the laparoscopic the manual scarring, received X challenge pain small for three lower is Senhance’s focused narcotic expansion groups instruments, instruments instruments. micro and manually use of diameter advanced instruments articulating clearance and first incisions controlling XXX(k) millimeter potential interface a FDA in in we growing of The instruments. millimeter digital October, X instruments, robotic-assisted of adoption X in addresses to The addition There smaller instruments.
X partners with millimeter instruments, robotic new from represent endoscopes our millimeter system surgery. vision each Our X coupled standard in a
for XXXX expansion was initiative articulating in portfolio instruments. Another
Mark quarter, clearance. for During expectations, for in fourth application we the articulating submitted and X instruments XXX(k) line with FDA approval CE received millimeter we our
and XXX(k) and expansion globe. instruments range the surgeons. and offering Ultrasonic, we with approval we of some are viewed versatile laparoscopy instrument to portfolio and Senhance the the this, use addition They received most and significant of the quarter energy The of system been surgery, accounts occurred additional enhancements as from dissections Senhance. with of the FDA tools for speed of fourth a of to the feedback laparoscopic our systems of attractiveness a for of with perform the the the FDA market urology an of visualization quarter the use. majority The these gynecologic U.S. provided Our of expanding instrument instrument. a the are CE XXXX, to HD most We compatibility across virtually have systems complex wide Shifting EU in all colorectal, the with X.X gynecology important Senhance XXXX October, XD We surgeries percentage offerings. bariatric, received the Ultrasonic Senhance, one to was Senhance. over of when to with instrument and general clearance. clinical in in and expand Ultrasonic as often has XXXX, laparoscopic In on gears broadens the for was including laparoscopic now Mark well believe approved safety. devices many capability excellent we compatibility as vision received instrument surgeons. surgeons fourth additional product Advanced in existing U.S. digital monitor the have critical for initiative addition used in Ultrasonic our the X to platform colorectal indications for high to and cases the end In energy continue subsequent leading for immediate across Xk with clearance access utilizing procedures. important surgeons Several most it’s device million and this begun in laparoscopic received Because initially for is surgery which advanced
specialties still over bringing for surgical was key would a more in remained this This procedures of that annually. tremendous our received U.S. While X the clearance the than bladder additional of we indications gall in adoption million we available Senhance believed addressable important to XXXX, the expanded In hernia procedures achievement, and total it market procedures. for FDA doubled May for be
This clearance, surgical in second was instruments. in received received which the the in approvals and around line countries was the receive approval quarter geographies. first we fourth for second for of to full which to In strategic a Senhance Senhance of initiative Asia. two system, FDA In the final XXXX. focused XXXX, primarily we Taiwanese regulatory required the of expectations, with clearances TFDA in was this quarter key Our expand
was Our in building a other focus foundation Japan. area
by discussed of also is assets patients, the process we or the to the capabilities XXXX, whose this medical eventual to MST In meaningfully past, these Japanese of the surgical to September, the behind in established we rooms we advance benefits acquisition the regulatory market second focused initiatives, believe image Israel-based market. will a we world’s and in company, largest subsidiary As continue to laparoscopy U.S. commercial on the advance surgery key the we of Outside med-tech globally. announced of operating In and have surgeons only robotics on technologies Japan technology of wanted Senhance. analytics focus in country needs digital
artificial cognition, underlying and Specifically, analytics are the key intelligence, same by image software-based powered technologies visualization, data learning machine advanced analytics.
are Senhance available We within volume sites number just we our Today, we surgeons the limited X limited expanded instruments just X the the into our available to significant clearance have and only the we in millimeter made XXXX, do indications efforts. size for in six launching progress surgical base throughout With we use total in its specialties. and market our one two surgery of system received observe significant very ultrasonic added surgical sale in different U.S. instrument very system. in high XXXX, the U.S., to As I U.S. is than quite year. we for the early the and stages reference two expanded double for with interact and expansions, have set a now. indications U.S. our systems. initial beginning In reviewed, and installed from specialties. Florida FDA use U.S. At commercial addressable of the We as for of had we sales instrument we had look
addressable market large opportunity. a have We
global key made similar access the the pipeline international the markets applicability and instruments for was growth into as in U.S. geographic our our expansion significantly added patients the In more of surgeon and to of both in hospitals it expanded in Senhance geographies. footprint surgeons shift in we had on instruments Senhance our of key our easier have in offering a product We terms preference key in to transformations surgeons, XXXX This and the driver significant expansion and our new we dynamic scale.
$X.X growth. both sold significant sales and in XXXX and XXXX for we systems Looking XXX% revenue, recognized performance a at growth. XX in in nearly sold and full we we and our revenue improvement the revenue million saw year, a five recognized In systems in $XX.X system million
to would Joe the into like We very review. go proud to the have been able provide now are what we call as XXXX. to the to have and XXXX all of foundation we over accomplish turn we in I financial established
